Expert design, execution, and reporting of package leaflet readability tests (“consultations with target patient groups”) for medicinal products. Pharmafile provides end-to-end management of the readability user testing process from study design and recruitment of target patient groups, through conducting interviews and analysing results, to compiling the official report for submission in Module 1.3.4 of your marketing authorisation application. Our specialists help you avoid common pitfalls in user consultation studies (such as poorly designed questionnaires or unrepresentative participants) and make certain that your package leaflet is fully compliant with Articles 59(3) and 61(1) of Directive 2001/83/EC, which require that the package leaflet reflects the results of consultations with target patient groups to ensure that it is legible, clear and easy to use, and that these results of assessments carried out in cooperation with target patient groups are also provided to the competent authority. We also advise on bridging strategies when appropriate enabling you to leverage existing user test results for similar leaflets and provide ongoing support to maintain leaflet readability throughout the product’s lifecycle. The European Commission’s Guideline on the Readability of the Labelling and Package Leaflet of Medicinal Products for Human Use (Revision 1, 12 January 2009), which came into operation on 12 June 2009 and superseded the 1998 version, provides the core framework we follow. The revision was prompted by the amendment of Directive 2001/83/EC by Directive 2004/27/EC. With Pharmafile’s support, you can confidently demonstrate to EMA, MHRA and other agencies that your product’s patient information has been thoroughly tested and optimised for patient comprehension, as required by European and UK law.
Readability User Testing – Clear & Compliant Patient Leaflets for EU & UK Medicines
Who This Service Is For
This service is designed for:
- Pharmaceutical Companies Preparing New or Updated Medicinal Products: Any company developing or marketing human medicines in the EU or UK that needs to fulfil the legal requirement for consultation with target patient groups (user testing) for their package leaflets. For all marketing authorisations granted after 30 October 2005, the rules outlined in the amended Directive 2001/83/EC must be followed, meaning all package leaflets in Community or national marketing authorisations need to be reviewed accordingly, and information about patient consultation must be included in the application dossier. This includes innovators and generic manufacturers seeking initial marketing authorisations, line extensions, or significant variations that necessitate proving the leaflet’s readability. Where the overall design and readability of the outer and immediate packaging or package leaflet is affected by a variation, the relevant authorities should be provided with mock-ups or specimens. We work with product development teams to plan and execute readability testing well ahead of submission deadlines, preventing last-minute delays in the registration process.
- Regulatory Affairs Teams Lacking In-House Testing Capabilities: Organisations that do not maintain an internal group for conducting user studies or that have limited experience with readability tests. We provide a turnkey solution recruiting appropriate patient participants, conducting the interviews, and preparing the required documentation so that your internal teams can focus on core regulatory tasks. This is particularly valuable for small to mid-sized MAHs or companies entering new markets (including the UK post-Brexit) who may be unfamiliar with local expectations for patient leaflet testing.
- Companies Managing Multiple or Multilingual Leaflets: Firms with portfolios of similar products or many language versions of a leaflet, who want to use efficient strategies like bridging to avoid repetitive testing. Bridging is a regulatory approach used when two or more package leaflets are sufficiently similar in both content and layout; a successful readability user test conducted on one leaflet the “parent” can be used to support another the “daughter” through a bridging report. For bridging to be acceptable, the “daughter” leaflet must follow the same design, layout, and writing style as the “parent”; if these elements differ significantly, the bridging proposal is unlikely to be accepted by the competent authority. If you market in numerous European countries, we ensure that a test conducted in one language can be reliably applied to other language versions and that any national-specific requirements are respected. National requirements vary significantly for example, in Poland, even minor changes such as adjustments to design, dimensions, or text layout are expected to be submitted to the Polish Medicines Agency (URPL).
- Parallel Importers and Niche Market MA Holders: Companies involved in parallel distribution or niche markets who must demonstrate that patient leaflets remain compliant when adapted or rebranded. We assist in obtaining necessary testing or preparing strong justifications, ensuring that even in these special scenarios, the PIL (Patient Information Leaflet) meets regulatory standards and can be approved without causing supply delays.
Who may not need this service: Veterinary product manufacturers (readability testing is currently not a formal requirement for veterinary medicines, as the legislative provisions in Article 59(3) of Directive 2001/83/EC apply to human medicinal products) or companies solely seeking general proofreading/translation of leaflets without needing formal user consultation. Our focus is on regulatory-driven user testing for human medicinal product leaflets; however, we can apply similar best practices to enhance veterinary or consumer health product literature on a case-by-case basis.
Regulatory Challenges We Address
Mandatory “User Testing” Compliance: EU law requires that patient leaflets for human medicines be consulted with target patient groups to confirm they are “legible, clear and easy to use”. The law does not define the precise method to be used; as a consequence, user testing has become the most common and accepted approach. Failing to provide adequate evidence of such consultation is a common reason for regulatory rejection or clock-stop during a marketing authorisation procedure. We ensure you meet this obligation by conducting or arranging formal readability tests and compiling the results in the prescribed format, for submission in Module 1.3.4 of the application dossier.
Designing Effective Tests Under Tight Timelines: User testing must be carefully planned and executed, often in parallel with other regulatory activities. A poorly designed test (e.g. using unrepresentative participants or leading questions) can yield misleading results, while a delayed test can hold up your submission. If a readability user testing report is not available at the time of initial submission, a commitment to submit it later during the procedure should be provided; the latest submission point for DCP/MRP new MAA procedures is the Day 160 responses, though this should be agreed upon with the Reference Member State (RMS) beforehand. Our early planning integrates the testing timeline into your overall submission schedule preparing the test protocol while your leaflet is in draft, so that testing can start as soon as a near-final text is available. This proactive approach prevents scenarios where an application is otherwise ready but paused because the readability report is not yet complete.
Ensuring Valid Outcomes and Acceptance Criteria: Regulators expect that at least 90% of participants must be able to locate and understand the key information presented in the leaflet. One challenge is achieving this high success criterion, especially for complex products with technical instructions or extensive side effect lists. Our experts mitigate this by advising on leaflet clarity from the outset (often recommending plain language edits before testing) and by iteratively testing and refining the leaflet. If the initial round of testing reveals problem areas, we revise the leaflet and re-test to ensure improvements. We fully document any issues and how they were resolved, as authorities will check that identified shortcomings were addressed.
Multiple Languages and National Nuances: While readability user testing for EU procedures can be conducted in any EU member state, for national procedures some National Competent Authorities (NCAs) may require the testing to be carried out within their own country. Sponsors should verify specific national requirements early in the planning process to ensure compliance. We navigate these nuances on your behalf: coordinating additional tests or targeted focus interviews in specific languages if required, or preparing suitable justification that a test in one language is applicable to another (with professional linguistic analysis). Our familiarity with both EMA and individual country expectations (including the MHRA’s policies post-Brexit) allows us to pre-empt national requirements and avoid last-minute requests that could delay approval.
Lifecycle Leaflet Updates: Once a medicinal product is on the market, the package leaflet may undergo changes for various reasons ranging from updates to safety or efficacy information, to adjustments in layout, design, or dimensions driven by commercial or practical considerations. These changes can impact the readability and usability of the leaflet and therefore may require additional regulatory steps. It is essential for MAHs to consult with the relevant NCA early in the process to determine whether submission of a new readability user test is required this is particularly important in national procedures, where local expectations may differ from those in centralised or decentralised procedures. We help you manage these challenges by assessing whether additional user testing or bridging is needed when you make post-approval changes, preventing potential non-compliance where authorities could find that a significantly altered leaflet was never re-tested for clarity.
Regulatory Requirements for Readability Testing
We start by clarifying the legal and procedural requirements that apply to your product’s package leaflet, to make sure we target the right strategy:
- Determining the Need for User Consultation: We confirm whether a full user test is required or if a bridging report or other justification can meet the requirement. For human medicines in the EU and UK, any new marketing authorisation or a significant variation impacting the leaflet’s content or layout triggers the need for consultation with target patient groups. If your product is a generic using a common leaflet format that has already been tested for the reference product, we might propose bridging to that existing test. Bridging allows the MAH to demonstrate compliance with Article 59(3) of Directive 2001/83/EC through a bridging report, provided the “daughter” leaflet follows the same design, layout, and writing style as the “parent”. Where the overall design and readability of the outer and immediate packaging or package leaflet is affected by the variation, we confirm that mock-ups or specimens will be provided to the relevant authorities as required. We also review any relevant national guidance’s for instance, some countries accept an EU user test performed in another language, while others may have stricter rules. It is essential for MAHs to consult with the relevant NCA early in the process to determine whether submission of a new readability user test is required.
- Developing a Compliance Plan: Once the strategy is settled (new test vs. bridging, etc.), we prepare a brief protocol or plan for the consultation. This document outlines how we will recruit participants, the proposed questionnaire format, the success criteria, and how we will document and report the findings. We share this plan with you and, if needed, can seek regulatory agreement in advance for unusual approaches. Our familiarity with EMA and MHRA procedures means we know when to proactively get buy-in for example, confirming with a Reference Member State in a DCP that a bridging proposal is acceptable to all Concerned Member States, in order to avoid late objections. This upfront planning ensures the actual testing phase proceeds smoothly and satisfies all regulatory expectations.
What Regulators Expect
Regulators in the EU and UK have well-defined expectations to ensure that patient leaflets are clear and have been adequately tested:
- Proof of Consultation with Patient Groups: For any new marketing authorisation (or relevant variation), the competent authority expects a formal demonstration that real patients find the leaflet understandable. In practice, this means submitting a readability user testing (RUT) report or a justified alternative. The results should be included in Module 1.3.4 of the application dossier and submitted with the new MAA at initial submission. For DCP/MRP new MAA procedures, the latest submission point is the Day 160 responses, subject to prior agreement with the RMS. Skipping this step or providing an inadequate report will almost certainly trigger regulatory questions or a validation refusal.
- Methodologically Sound Testing or Justified Alternatives: The law does not define the precise method to be used for patient consultation, but regulators have clear standards for any chosen method. User testing is described as a flexible development tool used to assess whether the content presents the intended information clearly, and the test itself could help to identify areas that may be confusing and need improvement. The testing process involves several critical steps:
- Participant selection: At least 20 participants from the target population are selected, representing the target patient population in terms of age, gender, education, and health literacy.
- Mock-up creation: A full-colour mock-up of the PIL is prepared for testing.
- Questionnaire design: The questionnaire should consist of open-ended, product-specific questions that assess whether users can locate and understand key information (e.g. dosage, contraindications, side effects); questions should be randomised in order, encouraging participants to search through different sections of the leaflet rather than relying on sequence; usually 12–15 questions are sufficient.
- Interview execution: Testing is conducted through structured, one-on-one interviews. The process includes pilot testing with 2 participants to refine the questionnaire and identify any major issues; the main testing phase should include at least 10 participants per round; at least two rounds are recommended to validate improvements and confirm consistent comprehension.
- Evaluation: At least 90% of participants must be able to locate and understand the key information presented in the leaflet.
- Report and submission: A report is created summarising the consultation process and results, and is submitted to EMA or national authorities for final evaluation.
- Comprehensive Documentation and Reporting: Regulators require a detailed readability testing report that covers the testing protocol, participant demographics, the full list of questions used, and the outcomes (including any difficulties observed and changes made as a result). They expect transparent reporting including any portions of the leaflet that participants struggled with and proof that you have modified the leaflet to resolve those issues. Based on the survey results, the Marketing Authorisation Holder may improve the leaflet, introduce more patient-friendly wording and improve design before submission of a new Marketing Authorisation Application. During dossier assessment (or inspections of the product information later on), authorities may check that the final leaflet in your submission corresponds to the one that passed testing, and that the test was conducted according to guidelines (e.g. interviewer records, anonymised response data, evidence that no coaching occurred).
- Appropriate Use of Bridging and Exemptions: Both EMA and national regulators accept bridging in lieu of a new user test if justified. Bridging is particularly useful when a product has multiple strengths or pharmaceutical forms; instead of conducting separate RUTs for each version, a single test may be performed for one, while bridging reports are submitted for the others saving time and resources during the marketing authorisation process. For bridging to be acceptable, the “daughter” leaflet must follow the same design, layout, and writing style as the “parent”. Certain package leaflets may require further user consultation to provide reassurance that patients will benefit from the information provided this is for example the case where user consultation is needed for recently approved package leaflets for a corresponding medicinal product, or those that reflect complex issues of risk communication which may need careful handling, or those that use medical terminology which requires detailed explanation.
- QRD Template Compliance Alone Is Insufficient: Member States and the European Medicines Agency agreed on harmonised Quality Review of Documents (QRD) templates for the package leaflet to ensure that the statutory information appears as intended by Directive 2001/83/EC. However, compliance with the QRD templates does not exempt from the obligation to undertake a user test or other form of user consultation. The content of package leaflets in the EU is guided by the QRD template (current version 10.4), which must follow a specific structure organised into defined sections: (1) What X is and what it is used for; (2) What you need to know before you take X; (3) How to take X; (4) Possible side effects; (5) How to store X; (6) Contents of the pack and other information. Template compliance must be supplemented by patient testing and full-colour mock-up formatting.
- Package Leaflet Readability Standards: The European Commission guideline provides extensive recommendations for creating clear, accessible, and patient-friendly package leaflets. Key recommendations from the guideline include:
Category Key Recommendations Type Size & Font A clear, easy-to-read font style is preferred, with a minimum size of 9 pt (e.g. Times New Roman) and at least 3 mm line spacing. Larger font sizes are recommended for materials intended for visually impaired patients Design & Layout Text should be left-aligned with sufficient spacing (e.g. 1.5× word spacing). Strong contrast between text and background improves readability. A column layout with clear separation and logical grouping of related content is considered effective Headings Consistent use of bold or coloured headings helps guide readers. A limited hierarchy (one to two levels) is generally more effective. The required headings under Article 59(1) should be included only when relevant Syntax Short, straightforward sentences and the use of bullet points (preferably limited to 5–6 items per list) enhance clarity. Side effects are more comprehensible when ordered by frequency, beginning with the most common Style An active voice and patient-focused language improve comprehension (e.g. referring to “your medicine” rather than the product name). Abbreviations and symbols should be limited and explained Paper Thick, uncoated paper reduces glare and prevents transparency from affecting readability. Leaflet folding should not obscure important information Symbols & Pictograms Non-promotional symbols and pictograms that support understanding may be included, provided they are widely recognised and tested for clarity. Pictograms should never replace essential written content
Study Design, Recruitment & Testing Methodology
We execute the user testing study using methodologies that align with the European Commission’s Readability Guideline and industry best practices, while avoiding biases and ensuring credible results:
- Participant Recruitment: We source and screen participants that reflect the target patient population of your medicine. Participants should represent the target patient population in terms of age, gender, education, and health literacy; at least 20 participants from the target population are selected. We deliberately avoid recruiting anyone with professional healthcare training or ties to the pharmaceutical industry, since regulators expect “layperson” feedback. We recruit participants in two sequential rounds of at least 10 for iterative testing. We also recruit a couple of reserve participants in case of drop-outs or to conduct a small pilot to fine-tune the process.
- Test Protocol & Questionnaire Design: We develop a structured protocol and a set of open-ended questions to probe how well users can find and comprehend critical information in the leaflet. The questionnaire is the primary tool for assessing comprehension; it should consist of open-ended, product-specific questions that assess whether users can locate and understand key information (e.g. dosage, contraindications, side effects). Questions should be randomised in order, encouraging participants to search through different sections of the leaflet rather than relying on sequence; usually 12–15 questions are sufficient. Additionally, general impression questions to gather feedback on layout, clarity, and overall usability should be included. We also prepare realistic full-colour mock-ups of the leaflet (in the actual or a simulated packaging layout, with accurate font size, columns, and colours) because regulators prefer testing on true-to-life materials, not just plain text documents.
- Conducting the Test: Testing is conducted through structured, one-on-one interviews; this approach allows for direct observation of how participants interact with the leaflet. Each session follows a consistent script: we ask participants to read the leaflet (or specific sections) and then answer the pre-set questions. We strictly observe best practices: no coaching or prompting beyond the neutral questions, allowing the participant to navigate the leaflet freely. The process includes pilot testing with 2 participants to refine the questionnaire and identify any major issues. The main testing phase includes at least 10 participants per round, with at least two rounds recommended to validate improvements and confirm consistent comprehension. After the first round, we analyse results to identify any problematic parts of the leaflet where multiple participants had trouble. We then recommend targeted improvements to wording or layout, update the leaflet, and conduct a second round with new participants to confirm that those changes resolved the issues.
- Success Criteria & Documentation: We apply the widely accepted success criterion: at least 90% of participants must be able to locate and understand the key information presented in the leaflet. We document each interview with the participants’ responses (anonymised) and any relevant observations (e.g. if a question had to be repeated, or a participant initially went to the wrong section). This granular documentation not only supports our analysis but is also kept on file in case an inspector or assessor requests more detail to audit the robustness of the test. By meticulously recording the methodology and outcomes, we ensure the results are credible, reproducible, and ready to be scrutinised by regulators.
Analysis, Reporting & Authority Submission
We compile the findings into a comprehensive Readability Test Report and handle all interactions with regulatory authorities regarding the user testing:
- Data Analysis & Leaflet Revision: After each testing round, our team analyses the responses to identify any trends. We pinpoint questions or sections where participants hesitated, gave incorrect answers, or appeared confused. Based on the survey results, the Marketing Authorisation Holder may improve the leaflet, introduce more patient-friendly wording and improve design before submission. We track all changes in a tabular format, which is later included in the report to show regulators an audit trail: original text, testing observations, and the resulting revision, demonstrating a commitment to continuous improvement of the leaflet’s clarity.
- Preparation of the Readability Test Report: A report is created summarising the consultation process and results. Our final report is structured to meet authority expectations, typically including: background (why the test was done), the test method and design (number of participants, demographics, setting, questionnaire, and procedure), the results (often summarised in a table showing each question, what percentage found and understood the information, and key findings), and conclusions. We clearly state whether the success criteria were met and, if not, what was done to achieve them. We append all necessary evidence: copies of the test questionnaire, the moderator’s guide, anonymised participant demographic data, and a summary of each interview’s outcome. For bridging reports, we describe the parent leaflet’s testing and justify the similarity, often including side-by-side comparisons of layout and content to show equivalence. Maintaining compliance throughout the product lifecycle requires proactive planning, thorough documentation of changes, and close alignment with national regulatory expectations. [
- Regulatory Submission & Follow-Up: We handle the submission of the readability documentation to the relevant authorities: inserting the user testing report or bridging report into Module 1.3.4 of the eCTD/NeeS submission and referencing it appropriately in the cover letter or application form. The report is submitted to EMA or national authorities for final evaluation. If the testing is not fully completed by initial submission, we craft a commitment statement (with regulatory approval) to provide it by a specific milestone the latest submission point for DCP/MRP new MAA procedures being the Day 160 responses, subject to prior agreement with the RMS. After submission, we remain available to respond to any authority questions on the consultation process.
Inspections, Deficiencies & Common Pitfalls
We prepare you to avoid and address the frequent pitfalls that can occur in the realm of user testing and satisfy inspectors or assessors reviewing your leaflet:
- Inadequate Testing or Documentation: A common mistake is assuming that a cursory check of the leaflet is sufficient. Regulators have flagged companies for submitting poorly designed tests for example, using too few participants or asking only closed yes/no questions, resulting in an insufficient demonstration of readability. We pre-empt this by following established standards (minimum 2 rounds, 20 people, open-ended questions, etc.) and by thoroughly documenting the methodology and results. By ensuring our report hits all the points’ inspectors look for, we mitigate the risk of a deficiency finding such as “User testing results not satisfactorily presented” or “Compliance with Article 59(3) not demonstrated.”
- Poor Participant Selection and Bias: Another frequent pitfall is choosing participants who are not representative of actual patients or inadvertently coaching them. Using pharmacy students to test a diabetes drug leaflet would draw regulator criticism, as would providing answers or hints during the test. We strictly recruit independent lay participants matching the patient profile and train our interviewers to avoid any leading prompts. If an inspector or auditor audits the user testing process, we have evidence ready: recruitment criteria, signed confidentiality agreements from participants, and even anonymised interview transcripts if needed. This level of detail assures authorities that the test was genuine and unbiased.
- Over-reliance on Templates or In-House Review: Some companies mistakenly believe that using the EMA’s QRD template and internal review by experts is enough to waive a patient test. Compliance with the QRD templates does not exempt from the obligation to undertake a user test or other form of user consultation. Template compliance alone does not ensure regulatory approval; templates must be supplemented by patient testing and full-colour mock-up formatting. We help you avoid this misstep by performing either a full user test or a justified alternative. Our team can advise when a justification might suffice, but in general, we err on the side of testing or bridging to be safe.
- Mismanaging Post-Approval Leaflet Changes: Once a product is on the market, companies sometimes modify their leaflets for readability or commercial reasons. A common oversight is failing to consider whether these changes themselves require regulatory notification or even re-testing. Once a medicinal product is on the market, the package leaflet may undergo changes for various reasons, and these changes can impact the readability and usability of the leaflet and therefore may require additional regulatory steps. It is essential for MAHs to consult with the relevant NCA early in the process to determine whether submission of a new RUT is required this is particularly important in national procedures, where local expectations may differ from those in centralised or decentralised procedures. We help you handle these changes correctly, assessing whether a bridging report to the original user test is warranted or whether the NCA expects a new round of testing.
Ongoing Readability & Lifecycle Support (Optional)
Ensuring a leaflet’s readability is an ongoing commitment. We offer continued support beyond the initial test to maintain and enhance leaflet quality over the product’s lifetime:
- Periodic Leaflet Reviews & Updates: We can conduct periodic reviews of your package leaflet, especially when there are cumulative changes over time. Even minor updates can gradually erode a leaflet’s clarity. The Regulatory Affairs function plays a key role not only in evaluating the suitability of bridging, but also in identifying the most effective and compliant approach for each specific case. Our team can re-evaluate the leaflet in light of these changes and recommend if a targeted user feedback session or simplified focus testing is advisable to verify that the leaflet remains clear.
- Bridging Reports for New Variants: As you develop new strengths, formulations, or dossiers for additional markets, we prepare bridging justifications to leverage existing user tests. Bridging is particularly useful when a product has multiple strengths or pharmaceutical forms; instead of conducting separate RUTs for each version, a single test may be performed for one, while bridging reports are submitted for the others. We have successfully used bridging in decentralised procedures where multiple language leaflets all follow the same format: testing one language and bridging to others by confirming accurate translation and identical layout, thus saving time and resources during the marketing authorisation process.
- Responding to Patient Feedback & Pharmacovigilance Insights: Sometimes real-world use uncovers issues that formal testing did not for instance, patients calling with recurring questions about the leaflet instructions, or medication errors traced to confusion from how something is worded. As part of our ongoing support, we can analyse such feedback (in collaboration with your PV team and medical information units) and suggest leaflet modifications to address them. We can then manage any necessary user re-testing of those sections or present a rationale for the change to regulators.
- Audit and Inspection Preparedness: If your pharmacovigilance or regulatory systems are audited (by internal auditors or inspectors from authorities), our team remains available to support any questions related to patient information consultations. We maintain archives of all testing documentation and correspondence. Our continued involvement means there is no lapse in knowledge the people who managed your user testing are on hand to respond to queries or to update the testing if regulations change.
Jurisdictions Covered
Our readability testing services are designed to meet the requirements of both European Union and United Kingdom regulators:
- European Union & EEA: We conduct user testing and prepare reports in accordance with Directive 2001/83/EC (as amended by Directive 2004/27/EC) and relevant EU guidance. Our methodologies align with the European Commission’s Guideline on the Readability of the Labelling and Package Leaflet of Medicinal Products for Human Use (Revision 1, 12 January 2009) and the CMDh guidance on consultations with target patient groups. Our deliverables (test protocols, reports, bridging justifications) are formatted for easy inclusion in centralised, decentralised, or national We take into account additional EMA considerations, such as the QRD templates (current version 10.4) and any product-specific risk communication needs that might require special testing focus. We have experience working with numerous EU member states’ national competent authorities and are familiar with their particular preferences. Readability user testing for EU procedures can be conducted in any EU member state, though for national procedures some NCAs may require the testing to be carried out within their own country.
- United Kingdom: The UK’s requirements for patient leaflet testing currently mirror the EU’s, as the substantive provisions of Directive 2001/83/EC were retained in UK law post-Brexit. The MHRA expects companies to demonstrate that package leaflets are user-tested or similarly consulted with patients, and to submit the results as part of the product licence application. We ensure that all our reports and processes meet MHRA’s format and content expectations. We leverage our knowledge of MHRA policies to your benefit, preparing strong rationales to avoid unnecessary testing. Additionally, we remain vigilant for any post-Brexit divergence: if the MHRA or other UK bodies introduce new guidance on patient engagement for leaflets, we quickly update our practices and will inform you of any impacts on your ongoing compliance.
- Global Coordination: While our focus is EU and UK, the principles of readability and patient-friendly information are globally recognised. If you are pursuing approvals in other regions, we can adapt our user testing reports or format to meet local expectations (some countries accept EU user testing data as supportive information). We have multilingual capabilities and can conduct patient leaflet testing in various languages if needed for specific markets.
Typical Timelines
The timeframe for conducting readability user testing can vary depending on factors such as participant recruitment speed and the need for multiple test rounds. Below is an indicative timeline assuming a standard user testing project for one package leaflet:
| Activity | Estimated Duration | Notes |
| Planning & Protocol Development | 1–2 weeks | Includes understanding the product, drafting the test protocol, designing the questionnaire, and obtaining any necessary regulatory alignment (e.g. agreement on bridging or test waiver). We often run pilot testing with 2 participants in this period to validate the questions and adjust as needed |
| Participant Recruitment & Scheduling | 2–3 weeks | Recruiting 20+ suitable participants (accounting for potential no-shows) typically takes a couple of weeks. Timing can be faster for broad-population products, but niche therapeutic areas (e.g. a leaflet for a rare disease medication where target patients are fewer) might extend recruitment time. We schedule interview sessions flexibly to expedite completion. |
| Round 1 User Testing (≥10 participants) | ~1 week (including analysis) | Conducting the first round of interviews usually spans a few days, followed by immediate analysis (1–2 days) to identify necessary leaflet modifications. We treat this as an iterative design sprint, so minimal time is lost between round 1 and implementing improvements |
| Leaflet Updates & Regulator Agreement | ~1 week | We revise the package leaflet based on round 1 findings. If round 1 uncovered significant issues, we may informally discuss these with the Reference Member State or Lead assessor to ensure our revision approach aligns with their expectations, avoiding surprises later. |
| Round 2 User Testing (≥10 new participants) | ~1 week (including analysis) | We recruit a fresh set of participants and run the second test round. Since changes are usually refinements, round 2 often goes quicker. We then finalise results and confirm that success criteria are met. If, in the rare case they are not (e.g. one question still falls short of the 90% comprehension threshold), we may perform a third mini-round focusing on that area, adding roughly 1 extra week. |
| Report Preparation & Quality Check | 1 week | We compile the readability test report (or bridging report), including all required attachments (questionnaire, individual response data summary, etc.). The draft is peer-reviewed internally to ensure it meets regulatory standards and clearly demonstrates that your leaflet passed the testing criteria. We aim to have the final report ready for submission by the time your registration dossier is otherwise complete. |
| Authority Review | Aligned with procedure timeline | In centralised or decentralised procedures, the user testing report is reviewed as part of the overall assessment (no separate clock). For DCP/MRP, the latest submission deadline is the Day 160 responses. We remain available to answer any questions during this review. |
(In urgent scenarios, we can expedite this schedule. For example, by drawing on an existing tested leaflet and focusing on bridging justification, we have delivered a complete bridging report in under 2 weeks. However, we advise building in sufficient time for robust testing to avoid rush situations.)
Common Mistakes We Help You Avoid
By leveraging our expertise, we prevent a number of frequent mistakes related to readability testing:
- Delaying or Omitting Required Testing: It is a costly error to treat user testing as an afterthought. Many companies have had their submissions validated only conditionally or delayed because the readability test was not ready or was missing entirely. We integrate the planning of user testing into your regulatory project plan from the start, ensuring it is completed in time for submission or authority deadlines. Module 1.3.4 should be submitted with new MAA at initial submission; if a readability user testing report is not available, a commitment to submit it later during the procedure should be submitted. By proactively scheduling and executing the test (or preparing a bridging report), we keep your approval timeline on track and your product launch on schedule.
- Improper Participant Selection or Conduct of Test: Another common pitfall is failing to execute the test under conditions that satisfy regulators. We have seen cases where companies used staff members or medically trained personnel as test participants an approach that authorities will reject as unrepresentative. In other instances, testers were asked leading questions or the testing was rushed through with insufficient analysis. Such errors can lead regulators to doubt the validity of the results and request a new test. Our team avoids these mistakes by recruiting independent lay participants matching the patient profile and following the established guidance for participant recruitment and interviewing technique: at least 20 participants from the target population, structured one-on-one interviews, and open-ended questions randomised in order, and at least two rounds with minimum 10 participants per round.
- Inadequate Documentation and Record-Keeping: Regulators expect to see not just a summary of results, but also evidence that the test was thoroughly documented. A mistake to avoid is providing a cursory report without supporting details (like participant demographics or the actual questions used). We produce a complete dossier of documentation: from recruitment forms and screening criteria, to anonymised answer sheets for each participant. Our meticulous records have often helped clients respond to authorities’ follow-up queries without needing to repeat any testing.
- Relying Solely on QRD Compliance or Internal Review: Companies sometimes assume that if the leaflet follows the QRD template and passes internal review by experts, a formal user test might be skipped. This is a misinterpretation of the requirements compliance with the QRD templates does not exempt from the obligation to undertake a user test or other form of user consultation. Additionally, experts are not stand-ins for real patients; what seems clear to a regulatory professional may confuse an average patient. We ensure you do not fall into this trap by verifying that your leaflet not only meets the template and linguistic requirements, but more importantly, that actual patients find it clear.
- Misjudging the Need for Re-testing After Changes: A final common mistake is assuming that once a leaflet has passed a user test, it never needs to be revisited. In reality, significant changes to a leaflet’s content or design can warrant another round of user consultation. National requirements vary significantly for example, in Poland, even minor changes such as adjustments to design, dimensions, or text layout are expected to be submitted to the Polish Medicines Agency (URPL), reflecting a stricter interpretation of national expectations. We guide you on when re-testing or bridging is necessary, using a proactive approach that prevents a scenario where a regulator or pharmacovigilance inspector points out that a modified leaflet could be confusing and asks for evidence that you confirmed its continued readability.
Readability testing (consultation with target patient groups) is required for virtually all new marketing authorisations for human medicines in the EU and UK, and whenever a package leaflet undergoes major changes that could impact comprehension. The requirement stems from EU law Articles 59(3) and 61(1) of Directive 2001/83/EC (as amended by Directive 2004/27/EC) which mandate that companies provide evidence that the leaflet is clear and understandable to patients. For all marketing authorisations granted after 30 October 2005, the rules outlined in the amended Directive must be followed, and information about patient consultation must be included in the application dossier. Minor wording changes or administrative updates usually do not require a new user test, but authorities will evaluate on a case-by-case basis.
A typical user test involves recruiting people from the medicine’s target audience and interviewing them individually about the content of the package leaflet. The questionnaire should consist of open-ended, product-specific questions that assess whether users can locate and understand key information; questions should be randomised in order, encouraging participants to search through different sections of the leaflet; usually 12–15 questions are sufficient. Testing is conducted through structured, one-on-one interviews, including pilot testing with 2 participants to refine the questionnaire, followed by the main testing phase with at least 10 participants per round and at least two rounds to validate improvements. At least 90% of participants must be able to locate and understand the key information presented in the leaflet. The results are compiled into a detailed report submitted to authorities as proof of compliance.
Yes, under certain conditions. This is known as “bridging.” Bridging is a regulatory approach used when two or more package leaflets are sufficiently similar in both content and layout; a successful RUT conducted on one leaflet the “parent” can be used to support another the “daughter” through a bridging report. For bridging to be acceptable, the “daughter” leaflet must follow the same design, layout, and writing style as the “parent”; if these elements differ significantly, the bridging proposal is unlikely to be accepted by the competent authority. Bridging is particularly useful when a product has multiple strengths or pharmaceutical forms instead of conducting separate RUTs for each version, a single test may be performed for one, while bridging reports are submitted for the others. The success of bridging depends on strong justification and regulatory acceptability; the Regulatory Affairs function plays a key role in evaluating the suitability of bridging and identifying the most effective approach for each specific case.
From start to finish, a straightforward readability user testing project typically takes around 6 to 8 weeks (planning estimate). This includes planning the test (1–2 weeks), recruiting participants (about 2 weeks), conducting two rounds of interviews and making leaflet adjustments (about 2–3 weeks total), and preparing the final report (1 week). We strongly recommend initiating the process early in your regulatory schedule. The results of user testing should be included in Module 1.3.4 of the application dossier and should ideally be submitted with the new MAA at initial submission. If that is not possible, the latest feasible time to provide it is typically during the regulatory clock-stop the latest submission point for DCP/MRP new MAA procedures being the Day 160 responses, subject to prior agreement with the RMS beforehand. Starting early not only avoids delaying approval, but it also provides an opportunity to improve the leaflet’s quality, reducing customer inquiries and medication errors.
No, usually one language test is sufficient, supported by high-quality translation and bridging. While readability user testing for EU procedures can be conducted in any EU member state, for national procedures some NCAs may require the testing to be carried out within their own country; sponsors should verify specific national requirements early in the planning process to ensure compliance. We normally conduct the test in a widely spoken language and ensure the final agreed text is then faithfully translated into all other required languages using the QRD templates. However, some NCAs may request additional evidence for specific languages for instance, if a language’s text length significantly alters the layout, or if a country has particular concerns. For example, in Poland, even minor changes such as adjustments to design, dimensions, or text layout are expected to be submitted to URPL, reflecting a stricter interpretation of national expectations where even small modifications may necessitate formal approval or additional justification.
It depends on the nature of the change. Minor textual updates or corrections (such as updating a telephone number, or adding a simple sentence) usually do not require a new user test you would justify that the change does not negatively impact readability. However, significant changes may warrant further consultation with patient groups. Once a medicinal product is on the market, the package leaflet may undergo changes for various reasons ranging from updates to safety or efficacy information, to adjustments in layout, design, or dimensions and these changes can impact the readability and usability of the leaflet and therefore may require additional regulatory steps. Where the overall design and readability of the package leaflet is affected by a variation, mock-ups or specimens should be provided to the relevant authorities. Bridging strategies may be applied in specific cases, but their success depends on strong justification and regulatory acceptability. Proactively managing leaflet changes helps avoid situations where an inconsistent or confusing leaflet remains on the market.
For veterinary medicines, formal user testing of package leaflets is not a standard regulatory requirement in the EU/UK in the way it is for human medicines. The legislative provisions for target patient consultation Articles 59(3) and 61(1) of Directive 2001/83/EC apply to human medicinal products. That said, some principles of clarity and readability still apply to veterinary product literature under good practice: the goal is for animal owners or handlers to understand how to use the product safely. While a veterinary product’s leaflet or labelling is usually intended for professional users (veterinarians or trained farmers), we do offer readability assessments or focus tests for veterinary products if needed. Similarly, for other healthcare products like OTC medicines, medical devices, or supplements, we can adapt our user testing approach in line with any applicable guidance.
We align every aspect of our service with official guidelines and past authority feedback. Before starting, we review relevant guidance including the European Commission’s Readability Guideline (Revision 1, 12 January 2009), the CMDh guidance on consultations with target patient groups, and MHRA user testing recommendations to confirm our approach matches current expectations. We only propose bridging when appropriate and always include a strong justification referencing the guiding principles same layout, same complexity, same target population ensuring the “daughter” leaflet follows the same design, layout, and writing style as the “parent”. Furthermore, we keep abreast of any regulatory changes and immediately implement those into our process. By being diligent and up-to-date, we minimise the chance that regulators could fault the methodology or relevance of your user test.
We can expedite certain steps using our experience and resources. For example, we maintain databases of pre-vetted participants (in various demographics) which can significantly cut down recruitment time. We also run multiple interviewers in parallel to handle more participants in a shorter window. However, there are practical and regulatory limits: the process of two sequential test rounds with analysis inherently takes a few weeks. The established methodology calls for at least 10 participants per round and at least two rounds skipping steps to save time would result in a substandard report that regulators might reject. Our strategy for urgent cases focuses on smart planning starting protocol development while your leaflet is still being finalised, and perhaps performing a pilot test on an early draft to catch glaring issues. It is always better to negotiate a slight extension with authorities (if needed) than to submit a rushed, inadequate test.
If a regulator raises concerns for example, if a member state in a DCP says they are not convinced by a bridging report or they find an aspect of the test report unsatisfactory we address it promptly and thoroughly. Typically, the concern will come as a request for clarification or additional data during the review process. In the case of a bridging report challenge, we might respond by providing supplemental evidence: perhaps showing comparative layout screenshots of the parent and daughter leaflets demonstrating they follow the same design, layout, and writing style, or offering to perform a focused mini-test on the differing section. If a concern is raised about the testing approach, we present additional analysis (e.g. pointing out the age distribution of participants) or offer a commitment to conduct a follow-up test if deemed necessary. Our role is to be your advocate and problem-solver: because we know the regulations and have encountered similar queries, we can formulate a persuasive response that satisfies the authority.
Related Services & Resources
Our Readability User Testing service naturally intersects with other aspects of product development and regulatory compliance. We ensure a seamless connection with these areas:
- Regulatory Writing & Submissions: The outcome of a readability test often necessitates changes to the package leaflet text. Our Medical Writing team can implement these improvements in the leaflet while preserving accuracy and compliance with the QRD template. We also handle all linguistic review steps (including managing translations across different EU languages, if needed). Once the leaflet text is final, our eCTD Publishing specialists compile the updated product information in the proper format for submission. (See our Medical Writing & eCTD Publishing service page for details on how we manage high-quality regulatory documents.)
- Braille Compliance: There is an overlap between ensuring written patient information is clear and making sure it is accessible to visually impaired patients. Article 56a of Directive 2001/83/EC requires the name of the medicinal product to be expressed in Braille format on the packaging, and the marketing authorisation holder to ensure that the package leaflet is made available in formats appropriate for the blind and partially sighted. On request from patients’ organisations, the package leaflet should be provided for partially-sighted people in a suitable print, taking into consideration all aspects determining the readability (e.g. font size: sans serif typefaces, 16–20 point, contrast: black letters on white paper, word spacing, text alignment, line spacing, layout, paper quality). For blind people the text has to be provided in an appropriate format; it is recommended to provide the text in a format perceptible by hearing (CD-ROM, audiocassette, etc.). Choice of the appropriate medium should be made by the marketing authorisation holder in consultation with representatives of organisations for the blind and partially sighted, and it is the responsibility of the MAH to provide the package leaflet on request from patients’ organisations in an appropriate format and to ensure that the current version is supplied. Our Braille Compliance Services complement readability testing by ensuring the finalised package leaflet text is accurately represented in Braille on the packaging. (Refer to our Braille Compliance Services page to understand how we manage Braille requirements in parallel with leaflet development.)
- Licensing & Regulatory Submissions: If you are licensing a product from another company (in-licensing) or out-licensing yours to a partner, you will need to ensure that the package leaflet supplied in the deal meets regulatory readability standards. Our Licensing Facilitation service dovetails with our readability testing expertise we often review incoming dossiers for compliance and identify if a new user test is needed for a local market or if existing tests can be bridged. We then execute any required testing on behalf of the licensee or help prepare the necessary documentation for the licence transfer. (See our Licensing In & Out Facilitation page for how we manage regulatory aspects in licensing deals.)
- Pharmacovigilance & Risk Communication: The clarity of patient information is a key component of risk minimisation. Our Pharmacovigilance Services team works closely with the readability testing unit when crafting Risk Management Plan (RMP) materials and additional risk minimisation measures that might accompany the leaflet (e.g. patient alert cards or guides). Certain package leaflets may require further user consultation where they reflect complex issues of risk communication which may need careful handling, or where they use medical terminology which requires detailed explanation. By integrating PV insights (such as known areas of patient confusion or medication errors) into the design of the leaflet and its testing, we improve patient comprehension and reduce the likelihood of misuse. (Refer to our Pharmacovigilance Services page for more on how we align safety communications with regulatory strategies.)
- Quality Assurance & Artwork Control: Implementation of readability recommendations can impact packaging and artwork. Our Quality Services team oversees the mock-up preparation and printing aspects: making sure that, for instance, if the readability test indicates a need for a larger font or different layout, the final technical artwork is updated and checked for consistency with what was tested. They also ensure that any changes to the leaflet’s physical properties (like paper size or fold type) are properly managed under your change control and technical agreements with printing vendors, as inspectors may verify how labelling changes are controlled. (See our Quality Services page for how we manage packaging quality and regulatory change controls.)

